Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2012

Open Access 01-12-2012 | Research article

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Authors: Michele Kohli, Donna Lawrence, Jennifer Haig, Andrea Anonychuk, Nadia Demarteau

Published in: BMC Public Health | Issue 1/2012

Login to get access

Abstract

Background

In Canada, two vaccines that have demonstrated high efficacy against infection with human papillomavirus (HPV) types −16 and −18 are available. The HPV-6/11/16/18 vaccine provides protection against genital warts (GW) while the HPV-16/18 vaccine may provide better protection against other oncogenic HPV types. In this analysis, the estimated clinical and economic benefit of each of these vaccines was compared in the Canadian setting.

Methods

A Markov model of the natural history of HPV infection among women, cervical cancer (CC) and GW was used to estimate the impact of vaccinating a cohort of 100,000 12-year-old females on lifetime outcomes and healthcare system costs (no indirect benefit in males included). A budget impact model was used to estimate the impact of each vaccine by province.

Results

In the base case, vaccination with the HPV-16/18 vaccine was predicted to prevent 48 additional CC cases, and 16 additional CC deaths, while vaccination with the HPV-6/11/16/18 vaccine was predicted to prevent 6,933 additional GW cases. Vaccination with the HPV-16/18 vaccine was estimated to save 1 additional discounted quality adjusted life year (QALY) at an overall lower lifetime cost to the healthcare system compared to the HPV-6/11/16/18 vaccine (assuming vaccine price parity). In sensitivity analyses, the HPV-6/11/16/18 vaccine was associated with greater QALYs saved when the cross-protection efficacy of the HPV-16/18 vaccine was reduced, or the burden of GW due to HPV-6/11 was increased. In most scenarios with price parity, the lifetime healthcare cost of the strategy with the HPV-16/18 vaccine was predicted to be lower than the HPV-6/11/16/18 vaccine. In the probabilistic sensitivity analyses, the HPV-16/18 vaccine provided more QALY benefit than the HPV-6/11/16/18 vaccine in 49.2% of scenarios, with lower relative lifetime costs in 83.5% of scenarios.

Conclusions

Overall, the predicted lifetime healthcare costs and QALYs saved by implementing each of the vaccines are similar. Vaccination with the HPV-16/18 vaccine is expected to be associated with reduced CC disease morbidity and mortality compared to vaccination with the HPV-6/11/16/18 vaccine. Differences in these outcomes depend on the extent of cervical disease prevented by cross-protection and the burden of GW caused by HPV-6/11.
Appendix
Available only for authorised users
Literature
1.
2.
Al-Daraji WI, Smith JH: Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol. 2009, 2: 48-64.PubMed
3.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
4.
Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL: Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006, 24: S26-S34.CrossRef
5.
Muñoz N, Bosch FX, De Sanjose S, Herrero R, Castellsagué X, Shah KV, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641.CrossRefPubMed
6.
Muñoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004, 111: 278-285. 10.1002/ijc.20244.CrossRefPubMed
7.
Bosch FX, Burchell AN, Schiffman M, Giuliano AR, De Sanjose S, Bruni L, et al: Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Vaccine. 2008, 26: K1-K16.CrossRefPubMed
8.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, et al: A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009, 10: 321-322. 10.1016/S1470-2045(09)70096-8.CrossRefPubMed
9.
Insight on Cancer: News and Information on Cervical Cancer. 2005, Toronto: Canadian Cancer Society (Ontario Division). Cancer Care Ontario
10.
11.
12.
Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, Pielak KL, et al: Parental intention to have daughters receive the human papillomavirus vaccine. Can Med Assoc J. 2007, 177: 1506-1512. 10.1503/cmaj.071022.CrossRef
13.
14.
15.
16.
17.
Colucci R, Hryniuk W, Savage C: HPV Vaccination Programs in Canada: Are we hitting the mark?. 2008, Report card on cancer in Canada
18.
19.
20.
21.
22.
23.
24.
Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006, 24: 5937-5949. 10.1016/j.vaccine.2006.06.005.CrossRefPubMed
25.
Skinner R, Apter D, Chow SN WCDG for the HPV PATRICIA Study Group: Cross-protection efficacy of Cervarix against oncogenic HPV types beyond HPV-16/18: Final analysis of cross-protection- PATRICIA STUDY. 2009, Malmö, Sweden: 25th International Papillomavirus Conference and Clinical Workshops
26.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009, 374: 301-314. 10.1016/S0140-6736(09)61248-4.CrossRefPubMed
27.
Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Mauricio HA, Wheeler CM, et al: The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009, 199: 926-935. 10.1086/597307.CrossRefPubMed
28.
Merck Canada Inc: GARDASIL® (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine). 2011, Health Canada: Product Monograph.Submission Control: 147972
29.
30.
Anonychuk A, Bauch C, Merid MF, Van Kriekinge G, Demarteau N: A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Publ Health. 2009, 9: 401-10.1186/1471-2458-9-401.CrossRef
31.
Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang KL, et al: Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine. 2008, 26: F46-F58.CrossRefPubMed
32.
Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, et al: Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine. 2008, 26: F16-F28.CrossRefPubMed
33.
Brisson M, van de Velde , De Wals P, Boily M-C: The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007, 25: 5399-5408. 10.1016/j.vaccine.2007.04.086.CrossRefPubMed
34.
Dee A, Howell F: A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health. 2010, 20: 213-219. 10.1093/eurpub/ckp141.CrossRefPubMed
35.
Ezat SW, Aljunid S: Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev. 2010, 11: 943-951.PubMed
36.
Mennini FS, Costa S, Favato G, Picardo M: Anti-HPV vaccination: a review of recent economic data for Italy. Vaccine. 2009, 27 (Suppl 1): A54-A61.CrossRefPubMed
37.
38.
Aljunid S, Zafar A, Saperi S, Amrizal M: Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination. Asian Pac J Cancer Prev. 2010, 11: 1551-1559.PubMed
39.
Capri S, Gasparini R, Panatto D, Demarteau N: Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecol Oncol. 2011, 121: 514-521. 10.1016/j.ygyno.2011.01.029.CrossRefPubMed
40.
Demarteau N, Standaert B: Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ. 2010, 13: 324-338. 10.3111/13696998.2010.490481.CrossRefPubMed
41.
Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011, 343: d5775-10.1136/bmj.d5775.CrossRefPubMedPubMedCentral
42.
Mauskopf JA, Earnshaw S, Mullins CD: Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005, 5: 65-79. 10.1586/14737167.5.1.65.CrossRefPubMed
43.
44.
Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA: Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2009, 85: 111-115.CrossRefPubMed
45.
46.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007, 369: 2161-2170. 10.1016/S0140-6736(07)60946-5.CrossRefPubMed
47.
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006, 367: 1247-1255. 10.1016/S0140-6736(06)68439-0.CrossRefPubMed
48.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004, 364: 1757-1765. 10.1016/S0140-6736(04)17398-4.CrossRefPubMed
49.
Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen O-E, et al: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006, 95: 1459-1466. 10.1038/sj.bjc.6603469.CrossRefPubMedPubMedCentral
50.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007, 356: 1928-1943. 10.1056/NEJMoa061760.CrossRefPubMed
51.
Tjalma W, Paavonen J, Naud P, Wheeler CM, Chow SN, et al: Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naïve population. 2009, Belgrade, Serbia: 16th International meeting of the European Society of Gynaecological Oncology (ESGO)
52.
53.
Bergeron C, Cartier I, Guldner L, Lassalle M, Savignoni A, Asselain B: Lesion precancereuses et cancers du col de l’uterus diagnostiques par le frottis cervical, Ile-de-France, enquete Crisap, 2002. Bulletin epidemiologique hebdomadaire. 2005, 2: 5-6.
54.
Krahn M, McLachlin M, Pham B, Rosen B, Sander B, Grootendorst P, et al: Liquid-based techniques for cervical cancer screening: a systematic review and cost-effectiveness analysis. 2008, Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health
55.
Suarez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, et al: Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008, 26: F29-F45.CrossRefPubMed
56.
57.
Insinga R, Glass A, Rush B: Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses. 2005, Vancouver, Canada: 22nd International Papillomavirus Conference & Clinical Workshops
58.
Myers ER, Green S, Lipkus I: Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation. 2004, Mexico City, Mexico: 21st International Papillomavirus Conference
59.
Institute Of Medicine: Financing vaccines in the 21st century: assuring access and availability. 2003, Washington DC: The National Academies Press
60.
WHO/ICO Information Centre of HPV and Cervical Cancer (HPV Information Centre): Human Papillomavirus and Related Cancer in North America. 2010, www.​who.​int/​hpvcentre.
61.
Aubin F, Prétet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, et al: Human papillomavirus genotype distribution in external acuminata condylomata: A large French national study (EDiTH IV). Clin Infect Dis. 2008, 47: 610-615. 10.1086/590560.CrossRefPubMed
62.
Keam SJ, Harper DM: Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [CervarixTM]. Drugs. 2008, 68: 359-372. 10.2165/00003495-200868030-00007.CrossRefPubMed
63.
Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis. 2009, 199: 936-944. 10.1086/597309.CrossRefPubMed
64.
Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010, 102: 325-339. 10.1093/jnci/djp534.CrossRefPubMed
65.
Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13: 100-110. 10.1016/S1470-2045(11)70287-X.CrossRefPubMed
66.
Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13: 89-99. 10.1016/S1470-2045(11)70286-8.CrossRefPubMed
67.
Guay M, ClouaÌtre A-M, Blackburn M, Baron G, De Wals P, Roy C, et al: Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren. Can J Public Health. 2003, 94: 64-67.PubMed
68.
World Health Organization: Preparing for the introduction of HPV vaccines: Policy and programme guidance for countries. 2006, Geneva: World Health Organization Press
69.
World Health Organization: Report of the consultation on human papillomavirus vaccines. 2005, Geneva: World Health Organization Press
70.
Woodhall S, Eriksson T, Nykanen AM, Huhtala H, Rissanen P, Apter D, et al: Impact of HPV vaccination on young women’s quality of life - a five year follow-up study. Eur J Contracept Reprod Health Care. 2011, 16: 3-8. 10.3109/13625187.2010.536921.CrossRefPubMed
71.
Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, et al: The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis. 2011, 38: 949-956. 10.1097/OLQ.0b013e3182215512.CrossRefPubMed
72.
Brisson M, van d V , Franco EL, Drolet M, Boily MC: Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011, 204: 372-376. 10.1093/infdis/jir285.CrossRefPubMed
73.
Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011, 11: 39-44. 10.1016/S1473-3099(10)70225-5.CrossRefPubMed
74.
Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, et al: Incidence of Genital Warts in Sweden Before and After Quadrivalent Human Papillomavirus Vaccine Availability. J Infect Dis. 2012
75.
Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001, 285: 2995-3002. 10.1001/jama.285.23.2995.CrossRefPubMed
76.
77.
Van de Velde N, Brisson M, Boily M-C: Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007, 165: 762-775. 10.1093/aje/kwk059.CrossRefPubMed
78.
Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, et al: Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer. 2001, 84: 796-801. 10.1054/bjoc.2000.1689.CrossRefPubMedPubMedCentral
79.
Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, et al: Incidence, clearance and predictors of human papillomavirus infection in women. Can Med Assoc J. 2003, 168: 421-425.
80.
Monsonego J, Breugelmans JG, Bouee S, Lafuma A, Benard S, Remy V: [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil. 2007, 35: 107-113. 10.1016/j.gyobfe.2006.12.010.CrossRefPubMed
81.
Fahey MT, Irwig L, Macaskill P: Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995, 141: 680-689.PubMed
82.
Gold MR, Franks P, McCoy KI, Fryback DG: Toward Consistency in Cost - Utility Analyses Using National Measures to Create Condition-Specific Values. Med Care. 1998, 36: 778-792. 10.1097/00005650-199806000-00002.CrossRefPubMed
83.
Villa LL, Perez G, Kjaer SK, Paavonen J, Lehtinen M, Muñoz N, et al: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007, 356: 1915-1927.CrossRef
84.
85.
Statistics Canada: Table 051–0001. Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual, CANSIM (database). 2010
86.
Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K: Genital warts and cost of care in England. Sex Transm Infect. 2011, 87: 464-468. 10.1136/sti.2010.048421.CrossRefPubMedPubMedCentral
87.
World Health Organization guide for the standardization of immunisation programmes: final version: Geneva. 2008, Switzerland: World Health Organization
88.
Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al: Comparison of the immunogenicity and safety of Cervarix® and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009, 5: 705-719. 10.4161/hv.5.10.9518.CrossRefPubMed
89.
Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, et al: Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from Months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 2011, 7: 1343-1358. 10.4161/hv.7.12.18281.CrossRefPubMedPubMedCentral
Metadata
Title
Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
Authors
Michele Kohli
Donna Lawrence
Jennifer Haig
Andrea Anonychuk
Nadia Demarteau
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2012
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-12-872

Other articles of this Issue 1/2012

BMC Public Health 1/2012 Go to the issue

Research article

Active living neighborhoods: is neighborhood walkability a key element for Belgian adolescents?

Research article

Progress towards implementation of ACT malaria case-management in public health facilities in the Republic of Sudan: a cluster-sample survey

Debate

Health systems frameworks in their political context: framing divergent agendas

Research article

Psychological characteristics in high-risk MSM in China

Research article

Validation of food store environment secondary data source and the role of neighborhood deprivation in Appalachia, Kentucky

Research article

Regional inequality and vaccine uptake: a multilevel analysis of the 2007 Welfare Monitoring Survey in Malawi